D-0042-2024 Class I

Recalled by Scynexis, Inc. — Jersey City, NJ

FDA drug recall D-0042-2024 was initiated by Scynexis, Inc. on Sep 25, 2023 and is designated Class I. Reason for recall: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound). Affected quantity: 17,376.

Recall details

Product Type
Drugs
Report Date
Oct 18, 2023
Initiation Date
Sep 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17,376

Product description

BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04

Reason for recall

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

Distribution pattern

Nationwide in the US.

Code information

Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0042-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0042-2024. Report a data issue: hello@regdatalab.com.